Clinical trial
A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
NCT04183166 is registered in ClinicalTrials.gov with Transgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
- Lead sponsor
- Transgene
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- December 12, 2019
- Completion date
- December 30, 2031
- Enrollment
- 80 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.